Assessment of gemcitabine hydrochloride-based nanotherapeutics in cancer: a proof of concept study
Source abstract
Abstract
Abstract Cancer remains a serious health problem in terms of incidence and mortality worldwide. As a result, researchers are working to identify new chemotherapeutic therapies or, potentially, to use innovative drug delivery methods in existing therapies. Recently, there has been a lot of interest in using nanocarriers as drug delivery systems, particularly for the treatment of cancer. Several novel nanocarrier-mediated drug delivery systems are currently being used to deliver chemotherapeutic agents to specific sites. Polymeric nanoparticles, liposomes, polymeric micelles, carbon nanotubes, dendrimers, solid lipid nanoparticles, magnetic nanoparticles and quantum dots are all examples of important nanocarriers. One of the most often prescribed chemotherapeutics for first-line therapy is gemcitabine hydrochloride, which has a broad spectrum of effects. Gemcitabine hydrochloride is an intriguing example of a drug for which various nanostructured targeted delivery methods are being explored over history. Even though some of these systems already exist on the market, there is continued research on this topic and new solutions are continually sought. In this context, the present review examines gemcitabine not as a specific drug, but as a proof of concept study that has drawn upon a wide range of innovative nanotechnology approaches. Graphical Abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–42410.3322/caac.21492 ↗
2. Rl S, Kd M, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):21254
3. Kairdolf BA, Smith AM, Stokes TH, Wang MD, Young AN, Nie S (2013) Semiconductor quantum dots for bioimaging and biodiagnostic applications. Annu Rev Anal Chem (Palo Alto, Calif) 6(1):14310.1146/annurev-anchem-060908-155136 ↗
4. Nandini PT, Doijad RC, Shivakumar HN, Dandagi PM (2015) Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Deliv 22(5):647–65110.3109/10717544.2013.860502 ↗
5. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G (2013) Nanotechnology in cancer therapy. J Drug Target 21(10):904–91310.3109/1061186X.2013.837469 ↗
6. Benko A, Medina-Cruz D, Vernet-Crua A, O’Connell CP, Świętek M, Barabadi H, Saravanan M, Webster TJ (2021) Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer. Cancer Drug Resist 4(2):264
7. Abdul Razak M, Devi Prasad Boggupalli S, Viswanath B (2015) Drug-loaded nanocarriers in tumor targeted drug delivery. Current. Biotechnology 4(3):319–344
8. Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105:11613–1161810.1073/pnas.0801763105 ↗
9. Khosravi-Darani K, Pardakhty A, Honarpisheh H, Rao VS, Mozafari MR (2007) The role of high-resolution imaging in the evaluation of nanosystems for bioactive encapsulation and targeted nanotherapy. Micron 38:804–81810.1016/j.micron.2007.06.009 ↗
10. Choi CH, Alabi CA, Webster P, Davis ME (2010) Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 107(3):1235–124010.1073/pnas.0914140107 ↗
11. Lei W, Yang C, Wu Y, Ru G, He X, Tong X, Wang S (2022) Nanocarriers surface engineered with cell membranes for cancer targeted chemotherapy. J Nanobiotechnol 20(1):1–2110.1186/s12951-021-01184-w ↗
12. Singhvi G, Rapalli VK, Nagpal S, Dubey SK, Saha RN (2020) Nanocarriers as potential targeted drug delivery for cancer therapy. In: Nanoscience in Medicine, vol 1. Springer, Cham, pp 51–88
13. Kairdolf BA et al (2013) Semiconductor quantum dots for bioimaging and biodiagnostic applications. Annu Rev Anal Chem 6:143–16210.1146/annurev-anchem-060908-155136 ↗
14. Dadwal A, Baldi A, Narang RK (2018) Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol 46(sup2):295–30510.1080/21691401.2018.1457039 ↗
15. Kumari P, Ghosh B, Biswas S (2016) Nanocarriers for cancer-targeted drug delivery. J Drug Target 24(3):179–19110.3109/1061186X.2015.1051049 ↗
16. Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M (2021) Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives. Int J Nanomed 16:1313–133010.2147/IJN.S289443 ↗
17. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A (2017) Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomed 12:7291–730910.2147/IJN.S146315 ↗
18. Lammers F, Kiessling WE, Hennink G (2012) Storm, Drug targeting to tumors principles, pitfalls and (pre-) clinical progress. J Control Release 161:175–18710.1016/j.jconrel.2011.09.063 ↗
19. Tian T, Ruan J, Zhang J, Zhao CX, Chen D, Shan J (2022) Nanocarrier-based tumor-targeting drug delivery systems for hepatocellular carcinoma treatments: enhanced therapeutic efficacy and reduced drug toxicity. J Biomed Nanotechnol 18(3):660–67610.1166/jbn.2022.3297 ↗
20. Yan L, Shen J, Wang J, Yang X, Dong S, Lu S (2020) Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response 18(3):155932582093616110.1177/1559325820936161 ↗
21. Abdul Razak M, Devi Prasad Boggupalli S, Viswanath B (2015) Drug-loaded nanocarriers in tumor targeted drug delivery. Curr Biotechnol 4(3):319–34410.2174/2211550104666150525221950 ↗
22. Han H, Li S, Zhong Y, Huang Y, Wang K, Jin Q, Ji J, Yao K (2021) Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. Asian J Pharm Sci10.1016/j.ajps.2021.06.001 ↗
23. Samanta K, Setua S, Kumari S, Jaggi M, Yallapu MM, Chauhan SC (2019) Gemcitabine combination nano therapies for pancreatic cancer. Pharmaceutics 11(11):57410.3390/pharmaceutics11110574 ↗
24. Shetty A, Nagesh PK, Setua S, Hafeez BB, Jaggi M, Yallapu MM, Chauhan SC (2020) Novel paclitaxel nanoformulation impairs de novo lipid synthesis in pancreatic cancer cells and enhances gemcitabine efficacy. ACS Omega 5(15):8982–899110.1021/acsomega.0c00793 ↗
25. Emamzadeh M, Pasparakis G. Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine. Sci Rep 2021;11(1):1-5.10.1038/s41598-021-88909-x ↗
26. Bhattacharya S, Anjum MM, Patel KK (2022) Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery. Drug Deliv 29(1):1060–107410.1080/10717544.2022.2058645 ↗
27. Stylianopoulos T, Wong C, Bawendi MG, Jain RK, Fukumura D (2012) Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol 508:109–13010.1016/B978-0-12-391860-4.00006-9 ↗
28. Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14(1):67–7710.18433/J30C7D ↗
29. Chen AM, Zhang M, Wei D et al (2009) Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5(23):2673–267710.1002/smll.200900621 ↗
30. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7:19310.3389/fmolb.2020.00193 ↗
31. Ranganathan R, Madanmohan S, Kesavan A et al (2012) Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomed 7:1043–1060
32. Hossen S, Hossain MK, Basher MK, Mia MN, Rahman MT, Uddin MJ (2019) Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res 15:1–810.1016/j.jare.2018.06.005 ↗
33. Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human health care. Nanomedicine 3(1):20–3110.1016/j.nano.2006.11.008 ↗
34. Dong X, Mumper RJ (2010) Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 5(4):597–61510.2217/nnm.10.35 ↗
35. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 9(1):1–210.1038/s41467-017-02088-w ↗
36. Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–78210.1038/nrd2614 ↗
37. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2:751–76010.1038/nnano.2007.387 ↗
38. Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14(1):67–7710.18433/J30C7D ↗
39. Dahiya S, Dahiya R, Hernández E (2021) Nanocarriers for anticancer drug targeting: recent trends and challenges. Crit Rev Ther Drug Carrier Syst 38(6)10.1615/CritRevTherDrugCarrierSyst.2021035650 ↗
40. Cho K, Wang X, Nie S, Chen Z, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–131610.1158/1078-0432.CCR-07-1441 ↗
41. Tapasya K, Kumar AS, Dharmarajan A, Parvathi VD (2022) Nanocarriers: the promising future to cancer diagnostics and treatment. Biomed Pharmacol J 15(2)10.13005/bpj/2416 ↗
42. Kaushik N, Borkar SB, Nandanwar SK et al (2022) Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnol 20:152. https://doi.org/10.1186/s12951-022-01364-210.1186/s12951-022-01364-2 ↗
43. Kenchegowda M, Rahamathulla M, Hani U, Begum MY, Guruswamy S, Osmani RAM, Gowrav MP, Alshehri S, Ghoneim MM, Alshlowi A, Gowda DV (2021) Smart nanocarriers as an emerging platform for cancer therapy: a review. Molecules 27(1):14610.3390/molecules27010146 ↗
44. Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135–14610.1016/j.jconrel.2010.08.027 ↗
45. Peer D, Karp J, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech 2:751–760. https://doi.org/10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
46. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136–15110.1016/j.addr.2010.04.009 ↗
47. Dastidar DG, Ghosh D, Das A (2022) Recent developments in nanocarriers for cancer chemotherapy. OpenNano:10008010.1016/j.onano.2022.100080 ↗
48. Huda S, Alam MA, Sharma PK (2020) Smart nanocarriers-based drug delivery for cancer therapy: an innovative and developing strategy. J Drug Deliv Sci Technol 60:10201810.1016/j.jddst.2020.102018 ↗
49. Fang Z, Shen Y, Gao D (2021) Stimulus-responsive nanocarriers for targeted drug delivery. New J Chem 45(10):4534–454410.1039/D0NJ05169A ↗
50. Neerooa BN, Ooi LT, Shameli K, Dahlan NA, Islam JM, Pushpamalar J, Teow SY (2021) Development of polymer-assisted nanoparticles and nanogels for cancer therapy: an update. Gels. 7(2):6010.3390/gels7020060 ↗
51. Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D (2021) Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol 12:60162610.3389/fphar.2021.601626 ↗
52. Resen AK, Atiroğlu A, Atiroğlu V, Eskiler GG, Aziz IH, Kaleli S, Özacar M (2022) Effectiveness of 5-Fluorouracil and gemcitabine hydrochloride loaded iron based chitosan-coated MIL-100 composite as an advanced, biocompatible, pH-sensitive and smart drug delivery system on breast cancer therapy. Int J Biol Macromol 198:175–18610.1016/j.ijbiomac.2021.12.130 ↗
53. İçhedef Ç, Teksöz S, Çetin O, Aydın B, Sarıkavak İ, Parlak Y, Bilgin BE (2021) Design of 99mTc radiolabeled gemcitabine polymeric nanoparticles as drug delivery system and in vivo evaluation. Mater Chem Phys 263:124380. https://doi.org/10.1016/j.matchemphys.2021.1210.1016/j.matchemphys.2021.12 ↗
54. García-García G, Fernández-Álvarez F, Cabeza L, Delgado ÁV, Melguizo C, Prados JC, Arias JL (2020) Gemcitabine-loaded magnetically responsive poly (ε-caprolactone) nanoparticles against breast cancer. Polymers 12(12):279010.3390/polym12122790 ↗
55. Emre Yalcin T, Ilbasmis-Tamer S, Takka S (2020) Antıtumor actıvıty of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNS) ın vıtro and ın vıvo. Int J Pharm:119246. https://doi.org/10.1016/j.ijpharm.2020.11924610.1016/j.ijpharm.2020.119246 ↗
56. Kush P, Bajaj T, Kaur M et al (2020) Biodistribution and pharmacokinetic study of gemcitabine hydrochloride loaded biocompatible iron-based metal organic framework. J Inorg Organomet Polym 30:2827–2841. https://doi.org/10.1007/s10904-019-01417-410.1007/s10904-019-01417-4 ↗
57. Jamil A, Mirza MA, Anwer K, Thakur PS, Alshahrani S, Alshetaili AS, Iqbal Z (2019) Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake and pharmacokinetic studies. Drug Dev Ind Pharm:1–34. https://doi.org/10.1080/03639045.2019.156904010.1080/03639045.2019.1569040 ↗
58. Yalcin TE, Ilbasmis-Tamer S, Takka S (2018) Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design. Int J Pharm 548(1):255–26210.1016/j.ijpharm.2018.06.063 ↗
59. Vandana M, Sahoo SK (2010) Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials 31(35):9340–935610.1016/j.biomaterials.2010.08.010 ↗
60. Alibolandi M, Ramezani M, Abnous K, Hadizadeh F (2016) AS1411 aptamer-decorated biodegradable polyethylene glycol–poly (lactic-co-glycolic acid) nanopolymersomes for the targeted delivery of gemcitabine to non–small cell lung cancer in vitro. J Pharm Sci 105(5):1741–174910.1016/j.xphs.2016.02.021 ↗
61. Yalcin TE, Ilbasmis-Tamer S, Ibisoglu B, Özdemir A, Ark M, Takka S (2018) Gemcitabine hydrochloride-loaded liposomes and nanoparticles: comparison of encapsulation efficiency, drug release, particle size, and cytotoxicity. Pharm Dev Technol 23(1):76–8610.1080/10837450.2017.1357733 ↗
62. Ghosh B, Biswas S (2021) Polymeric micelles in cancer therapy: state of the art. J Controll Release 332:127–147. https://doi.org/10.1016/j.jconrel.2021.02.01610.1016/j.jconrel.2021.02.016 ↗
63. Di Y, Gao Y, Gai X, Wang D, Wang Y, Yang X, Zhang D, Pan W, Yang X (2017) Co-delivery of hydrophilic gemcitabine and hydrophobic paclitaxel into novel polymeric micelles for cancer treatment. RSC Adv 7(39):24030–2403910.1039/C7RA02909H ↗
64. Norouzi P, Amini M, Dinarvand R, Arefian E, Seyedjafari E, Atyabi F (2020) Co-delivery of gemcitabine prodrug along with anti NF-κB siRNA by tri-layer micelles can increase cytotoxicity, uptake and accumulation of the system in the cancers. Mater Sci Eng C 116:111161. https://doi.org/10.1016/j.msec.2020.11116110.1016/j.msec.2020.111161 ↗
65. Wu LP, Ficker M, Christensen JB, Trohopoulos PN, Moghimi SM (2015) Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges. Bioconjug Chem 26(7):1198–121110.1021/acs.bioconjchem.5b00031 ↗
66. Esfand R, Tomalia DA (2001) Poly (amidoamine)(PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 6(8):427–43610.1016/S1359-6446(01)01757-3 ↗
67. Kesharwani P, Banerjee S, Gupta U, Amin MC, Padhye S, Sarkar FH, Iyer AK (2015) PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater Today 18(10):565–57210.1016/j.mattod.2015.06.003 ↗
68. Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D, Anderson CJ, Welch MJ, Fréchet JM (2009) Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA 106(3):685–69010.1073/pnas.0811757106 ↗
69. Sapsford KE, Algar WR, Berti L, Gemmill KB, Casey BJ, Oh E, Stewart MH, Medintz IL (2013) Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. Chem Rev 113(3):1904–207410.1021/cr300143v ↗
70. Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P (2020) Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today 25(1):223–22910.1016/j.drudis.2019.11.003 ↗
71. Hanurry EY, Mekonnen TW, Andrgie AT, Darge HF, Birhan YS, Hsu WH, Chou HY, Cheng CC, Lai JY, Tsai HC (2020) Biotin-decorated PAMAM G4. 5 dendrimer nanoparticles to enhance the delivery, anti-proliferative, and apoptotic effects of chemotherapeutic drug in cancer cells. Pharmaceutics 12(5):44310.3390/pharmaceutics12050443 ↗
72. Zhang C, Pan D, Li J, Hu J, Bains A, Guys N, Zhu H, Li X, Luo K, Gong Q, Gu Z (2017) Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy. Acta Biomater 55:153–16210.1016/j.actbio.2017.02.047 ↗
73. Zhang C, Pan D, Li J, Hu J, Bains A, Guys N, Zhu H, Li X, Luo K, Gong Q, Gu Z (2017) Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy. Acta Biomater 55:153–162. https://doi.org/10.1016/j.actbio.2017.02.04710.1016/j.actbio.2017.02.047 ↗
74. Bhargava S. 2018 Mannosylated poly (propylene imine) dendrimer mediated lung delivery of anticancer bioactive. In Pediatric Blood & Cancer (Vol. 65, pp. S417-S418). 111 River St, Hoboken 07030-5774, NJ USA: Wiley.
75. Öztürk K, Esendağlı G, Gürbüz MU, Tülü M, Çalış S (2017) Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers. Int J Pharm 517(1-2):157–16710.1016/j.ijpharm.2016.12.009 ↗
76. Parsian M, Mutlu P, Yalcin S, Tezcaner A, Gunduz U (2016) Half generations magnetic PAMAM dendrimers as an effective system for targeted gemcitabine delivery. Int J Pharm 515(1-2):104–11310.1016/j.ijpharm.2016.10.015 ↗
77. Soni N, Jain K, Gupta U, Jain NK (2015) Controlled delivery of gemcitabine hydrochloride using mannosylated poly (propyleneimine) dendrimers. J Nanopart Res 17(11):1–710.1007/s11051-015-3265-1 ↗
78. Pourjavadi A, Tehrani ZM, Moghanaki AA (2016) Folate-conjugated pH-responsive nanocarrier designed for active tumor targeting and controlled release of gemcitabine. Pharm Res 33(2):417–43210.1007/s11095-015-1799-7 ↗
79. Yalçın S, Erkan M, Ünsoy G, Parsian M, Kleeff J, Gündüz U (2014) Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. Biomed Pharmacother 68(6):737–74310.1016/j.biopha.2014.07.003 ↗
80. Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B (2018) Gold nanoparticles in cancer treatment. Mol Pharm 16(1):1–2310.1021/acs.molpharmaceut.8b00810 ↗
81. Emamzadeh M, Pasparakis G (2021) Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine. Sci Rep 11:940410.1038/s41598-021-88909-x ↗
82. Lin L, Fan Y, Gao F, Jin L, Li D, Sun W, Li F, Qin P, Shi Q, Shi X, Du L (2018) UTMD-promoted co-delivery of gemcitabine and miR-21 inhibitor by dendrimer-entrapped gold nanoparticles for pancreatic cancer therapy. Theranostics 8(7):192310.7150/thno.22834 ↗
83. Huai Y, Zhang Y, Xiong X, Das S, Bhattacharya R, Mukherjee P (2019) Gold nanoparticles sensitize pancreatic cancer cells to gemcitabine. Cell Stress 3(8):267–279. https://doi.org/10.15698/cst2019.08.19510.15698/cst2019.08.195 ↗
84. Devi L, Gupta R, Jain SK, Singh S, Kesharwani P (2020) Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of gemcitabine with natural polysaccharides for treatment of breast cancer. J Drug Deliv Sci Technol 56:10156510.1016/j.jddst.2020.101565 ↗
85. Guemei AA, Dessouky E, Shalaby TI, Amer SK, Nassra R (2021) Study of the efficacy and multidrug resistance using gold nanoparticles-based drug delivery versus conventional chemotherapy in non-small-cell lung cancer cell line. Res Oncol 17(2):42–5010.21608/resoncol.2021.70125.1134 ↗
86. Waghmare MN, Qureshi TS, Krishna CM, Pansare K, Gadewal N, Hole A, Dongre PM (2022) β-Lactoglobulin-gold nanoparticles interface and its interaction with some anticancer drugs–an approach for targeted drug delivery. J Biomol Struct Dyn 40(13):6193–621010.1080/07391102.2021.1879270 ↗
87. Waghmare MN, Qureshi TS, Shaikh AN, Khade BS, Murali Krishna C, Dongre PM (2020) Functionalized alpha-lactalbumin conjugated with gold nanoparticle for targeted drug delivery. Chem Select 5(6):2035–2049
88. Huai Y, Zhang Y, Xiong X, Das S, Bhattacharya R, Mukherjee P (2019) Gold nanoparticles sensitize pancreatic cancer cells to gemcitabine. Cell Stress 3(8):26710.15698/cst2019.08.195 ↗
89. Wang Z, Chen L, Chu Z, Huang C, Huang Y, Jia N (2018) Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging. Mater Sci Eng C 89:106–11810.1016/j.msec.2018.03.025 ↗
90. Santiago T, DeVaux RS, Kurzatkowska K, Espinal R, Herschkowitz JI, Hepel M (2017) Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine. Int J Nanomed 12:7763–7776. https://doi.org/10.2147/IJN.S14930610.2147/IJN.S149306 ↗
91. Pal K, Al-Suraih F, Gonzalez-Rodriguez R, Dutta SK, Wang E, Kwak HS, Caulfield TR, Coffer JL, Bhattacharya S (2017) Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer. Nanoscale 9(40):15622–1563410.1039/C7NR03172F ↗
92. Rhamani S, Chaix A, Aggad D, Hoang P, Moosa B, Garcia M, Gary-Bobo M, Charnay C, Almalik A, Durand JO, Khashab NM. Gold core mesoporous organosilica shell degradable nanoparticles for two-photon imaging and gemcitabine monophosphate delivery 2017.10.1039/C7ME00058H ↗
93. Pooja D, Panyaram S, Kulhari H, Reddy B, Rachamalla SS, Sistla R (2015) Natural polysaccharide functionalized gold nanoparticles as biocompatible drug delivery carrier. Int J Biol Macromol 80:48–5610.1016/j.ijbiomac.2015.06.022 ↗
94. Raoof M, Corr SJ, Zhu C, Cisneros BT, Kaluarachchi WD, Phounsavath S, Wilson LJ, Curley SA (2014) Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomed Nanotechnol Biol Med 10(6):1121–113010.1016/j.nano.2014.03.004 ↗
95. Singh R, Deshmukh R (2022) Carbon nanotube as an emerging theranostic tool for oncology. J Drug Deliv Sci Technol:10358610.1016/j.jddst.2022.103586 ↗
96. Tang L, Xiao Q, Mei Y et al (2021) Insights on functionalized carbon nanotubes for cancer theranostics. J Nanobiotechnol 19:423. https://doi.org/10.1186/s12951-021-01174-y10.1186/s12951-021-01174-y ↗
97. Das S, Desai JL, Thakkar HP (2013) Gemcitabine hydrochloride-loaded functionalised carbon nanotubes as potential carriers for tumour targeting. Indian J Pharm Sci 75(6):707–715
98. Razzazan A, Atyabi F, Kazemi B, Dinarvand R (2016) Influence of PEG molecular weight on the drug release and in vitro cytotoxicity of single-walled carbon nanotubes-PEG-gemcitabine conjugates. Curr Drug Deliv 13(8):1313–132410.2174/1567201813666160111123947 ↗
99. Zhang P, Yi W, Hou J, Yoo S, Jin W, Yang Q (2018) A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer. Int J Nanomed 13:3069–308010.2147/IJN.S165232 ↗
100. Yang F, Jin C, Yang D, Jiang Y, Li J, Di Y, Hu J, Wang C, Ni Q, Fu D (2011) Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment. Eur J Cancer 47(12):1873–188210.1016/j.ejca.2011.03.018 ↗